{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:58:12Z","timestamp":1789750692560,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"DOI":"10.7759\/cureus.87122","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T17:30:02Z","timestamp":1751391002000},"source":"Crossref","is-referenced-by-count":1,"title":["Management of Anticoagulation in Antiphospholipid Syndrome and Systemic Lupus Erythematosus With Concurrent Thrombosis and Hemorrhage"],"prefix":"10.7759","author":[{"given":"Teresa","family":"Mota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Queir\u00f3s Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Le\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia D","year":"2018","unstructured":"Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018, 378:2010-21. 10.1056\/NEJMra1705454","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli L","year":"2013","unstructured":"Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken). 2013, 65:1869-73. 10.1002\/acr.22066","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera R","year":"2015","unstructured":"Cervera R, Serrano R, Pons-Estel GJ, et al.. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015, 74:1011-8. 10.1136\/annrheumdis-2013-204838","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310388445","article-title":"International consensus for a definition of disease flare in lupus","volume":"20","author":"Ruperto N","year":"2011","unstructured":"Ruperto N, Hanrahan LM, Alarc\u00f3n GS, et al.. International consensus for a definition of disease flare in lupus. Lupus. 2011, 20:453-62. 10.1177\/0961203310388445","journal-title":"Lupus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis S","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006, 4:295-306. 10.1111\/j.1538-7836.2006.01753.x","journal-title":"J Thromb Haemost"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis A","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, et al.. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019, 78:736-45. 10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza G","year":"2010","unstructured":"Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010, 376:1498-509. 10.1016\/S0140-6736(10)60709-X","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros J","year":"2019","unstructured":"Ordi-Ros J, S\u00e1ez-Comet L, P\u00e9rez-Conesa M, et al.. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med. 2019, 171:685-94. 10.7326\/M19-0291","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15158","article-title":"Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): two-year outcomes after the study closure","volume":"19","author":"Pengo V","year":"2021","unstructured":"Pengo V, Hoxha A, Andreoli L, et al.. Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): two-year outcomes after the study closure. J Thromb Haemost. 2021, 19:531-5. 10.1111\/jth.15158","journal-title":"J Thromb Haemost"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2013.74.4.151","article-title":"Diffuse alveolar hemorrhage","volume":"74","author":"Park MS","year":"2013","unstructured":"Park MS. Diffuse alveolar hemorrhage. Tuberc Respir Dis (Seoul). 2013, 74:151-62. 10.4046\/trd.2013.74.4.151","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000291","article-title":"Systematic review of diffuse alveolar hemorrhage in systemic lupus erythematosus: focus on outcome and therapy","volume":"21","author":"Ednalino C","year":"2015","unstructured":"Ednalino C, Yip J, Carsons SE. Systematic review of diffuse alveolar hemorrhage in systemic lupus erythematosus: focus on outcome and therapy. J Clin Rheumatol. 2015, 21:305-10. 10.1097\/RHU.0000000000000291","journal-title":"J Clin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia DA","year":"2012","unstructured":"Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012, 141:e24S-43S. 10.1378\/chest.11-2291","journal-title":"Chest"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000117","article-title":"Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival","volume":"2","author":"Kazzaz NM","year":"2015","unstructured":"Kazzaz NM, Coit P, Lewis EE, McCune WJ, Sawalha AH, Knight JS. Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival. Lupus Sci Med. 2015, 2:e000117. 10.1136\/lupus-2015-000117","journal-title":"Lupus Sci Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/art.40937","article-title":"Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases","volume":"71","author":"Md Yusof MY","year":"2019","unstructured":"Md Yusof MY, Vital EM, McElvenny DM, et al.. Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2019, 71:1812-23. 10.1002\/art.40937","journal-title":"Arthritis Rheumatol"},{"key":"ref15","article-title":"Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases","volume":"28","author":"Ramos-Casals M","year":"2010","unstructured":"Ramos-Casals M, Garc\u00eda-Hernandez FJ, de Ram\u00f3n E, et al.. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010, 28:468-76.","journal-title":"Clin Exp Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6031053","article-title":"Efficacy of rituximab in a systemic lupus erythematosus patient presenting with diffuse alveolar hemorrhage","volume":"2017","author":"Montes-Rivera G","year":"2017","unstructured":"Montes-Rivera G, R\u00edos G, Vil\u00e1 LM. Efficacy of rituximab in a systemic lupus erythematosus patient presenting with diffuse alveolar hemorrhage. Case Rep Rheumatol. 2017, 2017:6031053. 10.1155\/2017\/6031053","journal-title":"Case Rep Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.843718","article-title":"Patterns of recurrent thrombosis in primary antiphospholipid syndrome-multicenter, real-life long-term follow-up","volume":"13","author":"Niznik S","year":"2022","unstructured":"Niznik S, Rapoport MJ, Avnery O, Lubetsky A, Haj Yahia S, Ellis MH, Agmon-Levin N. Patterns of recurrent thrombosis in primary antiphospholipid syndrome-multicenter, real-life long-term follow-up. Front Immunol. 2022, 13:843718. 10.3389\/fimmu.2022.843718","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102327","article-title":"Bleeding events in thrombotic antiphospholipid syndrome: prevalence, severity, and associated damage accrual","volume":"8","author":"Gaspar P","year":"2024","unstructured":"Gaspar P, Mittal P, Cohen H, Isenberg DA. Bleeding events in thrombotic antiphospholipid syndrome: prevalence, severity, and associated damage accrual. Res Pract Thromb Haemost. 2024, 8:102327. 10.1016\/j.rpth.2024.102327","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/370406-management-of-anticoagulation-in-antiphospholipid-syndrome-and-systemic-lupus-erythematosus-with-concurrent-thrombosis-and-hemorrhage","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T17:30:03Z","timestamp":1751391003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/370406-management-of-anticoagulation-in-antiphospholipid-syndrome-and-systemic-lupus-erythematosus-with-concurrent-thrombosis-and-hemorrhage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.87122","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}